Verastem, Inc. (VSTM)
About Verastem, Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $30.9M
- Net income
- -$209.5M
- Total assets
- $246.4M
- Market cap
- $531.6M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $531.6M
- Shares outstanding
- 53.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 27, 2012
Verastem, Inc. (VSTM) Stock Price
- Reported a net loss of $209.5M in FY2025.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Verastem, Inc..
Write a review
News about Verastem, Inc.
News & sentiment via Polygon.io
Verastem, Inc.: frequently asked questions
Is Verastem, Inc. an American company?
Verastem, Inc. is a US-based company headquartered in Needham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Verastem, Inc. headquartered?
Verastem, Inc. is headquartered in Needham, Massachusetts, United States.
Is Verastem, Inc. publicly traded?
Yes — Verastem, Inc. is a publicly traded company. Its stock trades under the ticker symbol VSTM on the NASDAQ.
What does Verastem, Inc. do?
Verastem, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Verastem, Inc. founded?
Verastem, Inc. was founded in 2010.
